Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the steady-state zanubrutinib
pharmacokinetics (PK) when coadministered with moderate and strong cytochrome P450 A (CYP3A)
inhibitors.